Study of Nivolumab for Advanced Cancers in India

Safety Study of Nivolumab for Selected Advanced Malignancies in India

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy OR advanced renal cell carcinoma (RCC) after prior therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization

Exclusion Criteria:

• Participants with untreated, symptomatic central nervous system (CNS) metastases
• Participants with carcinomatous meningitis
• Participants with active, known or suspected autoimmune disease
• Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
• Other active malignancy requiring concurrent intervention

Other protocol defined inclusion/exclusion criteria could apply